{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:54:05Z","timestamp":1790902445015,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Seoul National University Bundang Hospital Research Fund","award":["No. 14-2022-0006"],"award-info":[{"award-number":["No. 14-2022-0006"]}],"id":[{"id":"https:\/\/ror.org\/00cb3km46","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Research Foundation (NRF) of Korea","award":["RS-2023-00249667"],"award-info":[{"award-number":["RS-2023-00249667"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10120-025-01669-9","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T19:43:13Z","timestamp":1759434193000},"page":"1144-1157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2413-5287","authenticated-orcid":false,"given":"Sung-Hyun","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-9074","authenticated-orcid":false,"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeseong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songji","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woochan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongmin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejung","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hee","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"issue":"3","key":"1669_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1669_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4143\/crt.2025.264","volume":"57","author":"EH Park","year":"2025","unstructured":"Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2022. Cancer Res Treat. 2025;57(2):312\u201330.","journal-title":"Cancer Res Treat"},{"issue":"7903","key":"1669_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942\u20138.","journal-title":"Nature"},{"issue":"1","key":"1669_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","volume":"17","author":"N Boku","year":"2014","unstructured":"Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17(1):1\u201312.","journal-title":"Gastric Cancer"},{"issue":"13","key":"1669_CR5","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","volume":"381","author":"DF Hayes","year":"2019","unstructured":"Hayes DF. HER2 and breast cancer - a phenomenal success story. N Engl J Med. 2019;381(13):1284\u20136.","journal-title":"N Engl J Med"},{"issue":"25","key":"1669_CR6","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"9742","key":"1669_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"24","key":"1669_CR8","doi-asserted-by":"publisher","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","volume":"15","author":"PR Pohlmann","year":"2009","unstructured":"Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in breast cancer. Clin Cancer Res. 2009;15(24):7479\u201391.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1669_CR9","doi-asserted-by":"publisher","first-page":"886","DOI":"10.4143\/crt.2018.375","volume":"51","author":"AR Nam","year":"2019","unstructured":"Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, et al. Jab1 silencing inhibits proliferation and sensitizes to Cisplatin in biliary tract cancer. Cancer Res Treat. 2019;51(3):886\u2013900.","journal-title":"Cancer Res Treat"},{"issue":"5593","key":"1669_CR10","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1126\/science.1075901","volume":"298","author":"GA Cope","year":"2002","unstructured":"Cope GA, Suh GS, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, et al. Role of predicted metalloprotease motif of Jab1\/Csn5 in cleavage of Nedd8 from Cul1. Science. 2002;298(5593):608\u201311.","journal-title":"Science"},{"issue":"3","key":"1669_CR11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170(3):564-76 e16.","journal-title":"Cell"},{"issue":"1","key":"1669_CR12","doi-asserted-by":"publisher","first-page":"13166","DOI":"10.1038\/ncomms13166","volume":"7","author":"A Schlierf","year":"2016","unstructured":"Schlierf A, Altmann E, Quancard J, Jefferson AB, Assenberg R, Renatus M, et al. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat Commun. 2016;7(1):13166.","journal-title":"Nat Commun"},{"issue":"3","key":"1669_CR13","first-page":"71","volume":"3","author":"X Rao","year":"2013","unstructured":"Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Biopharm Biomath. 2013;3(3):71\u201385.","journal-title":"Biostat Biopharm Biomath"},{"issue":"1","key":"1669_CR14","doi-asserted-by":"publisher","first-page":"12308","DOI":"10.1038\/s41598-020-68998-w","volume":"10","author":"KJ Kim","year":"2020","unstructured":"Kim KJ, Kim JW, Sung JH, Suh KJ, Lee JY, Kim SH, et al. Pi3k-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. Sci Rep. 2020;10(1):12308.","journal-title":"Sci Rep"},{"issue":"5","key":"1669_CR15","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1128\/MCB.02061-07","volume":"28","author":"M Escriva","year":"2008","unstructured":"Escriva M, Peiro S, Herranz N, Villagrasa P, Dave N, Montserrat-Sentis B, et al. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol. 2008;28(5):1528\u201340.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"1669_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/pros.22974","volume":"75","author":"B Uygur","year":"2015","unstructured":"Uygur B, Abramo K, Leikina E, Vary C, Liaw L, Wu WS. SLUG is a direct transcriptional repressor of PTEN tumor suppressor. Prostate. 2015;75(9):907\u201316.","journal-title":"Prostate"},{"issue":"29","key":"1669_CR17","doi-asserted-by":"publisher","first-page":"20670","DOI":"10.18632\/oncotarget.25060","volume":"9","author":"K Watanabe","year":"2018","unstructured":"Watanabe K, Yokoyama S, Kaneto N, Hori T, Iwakami Y, Kato S, et al. COP9 signalosome subunit 5 regulates cancer metastasis by deubiquitinating SNAIL. Oncotarget. 2018;9(29):20670\u201380.","journal-title":"Oncotarget"},{"issue":"2","key":"1669_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117\u201327.","journal-title":"Cancer Cell"},{"issue":"6","key":"1669_CR19","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925\u201339.","journal-title":"Cancer Cell"},{"key":"1669_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.omto.2019.12.013","volume":"16","author":"Y-S Ma","year":"2020","unstructured":"Ma Y-S, Wang X-F, Zhang Y-J, Luo P, Long H-D, Li L, et al. Inhibition of USP14 deubiquitinating activity as a potential therapy for tumors with p53 deficiency. Molecular Therapy-Oncolytics. 2020;16:147\u201357.","journal-title":"Molecular Therapy-Oncolytics"},{"issue":"12","key":"1669_CR21","doi-asserted-by":"publisher","first-page":"e12553","DOI":"10.1016\/j.heliyon.2022.e12553","volume":"8","author":"L Wang","year":"2022","unstructured":"Wang L, Zeng X, Yang G, Liu G, Pan Y. Pan-cancer analyses of Jab1\/COPS5 reveal oncogenic role and clinical outcome in human cancer. Heliyon. 2022;8(12):e12553.","journal-title":"Heliyon"},{"key":"1669_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fphar.2018.00135","volume":"9","author":"G Liu","year":"2018","unstructured":"Liu G, Claret FX, Zhou F, Pan Y. Jab1\/COPS5 as a novel biomarker for diagnosis, prognosis, therapy prediction and therapeutic tools for human cancer. Front Pharmacol. 2018;9:135.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1669_CR23","doi-asserted-by":"publisher","first-page":"9013","DOI":"10.1038\/s41598-021-88331-3","volume":"11","author":"D Yokoyama","year":"2021","unstructured":"Yokoyama D, Hisamori S, Deguchi Y, Nishigori T, Okabe H, Kanaya S, et al. PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma. Sci Rep. 2021;11(1):9013.","journal-title":"Sci Rep"},{"key":"1669_CR24","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10120-016-0627-z","volume":"20","author":"Y Deguchi","year":"2017","unstructured":"Deguchi Y, Okabe H, Oshima N, Hisamori S, Minamiguchi S, Muto M, et al. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. Gastric Cancer. 2017;20:416\u201327.","journal-title":"Gastric Cancer"},{"issue":"5","key":"1669_CR25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-17-2781","volume":"24","author":"F Pietrantonio","year":"2018","unstructured":"Pietrantonio F, Fuc\u00e0 G, Morano F, Gloghini A, Corso S, Aprile G, et al. Biomarkers of primary resistance to trastuzumab in HER2-Positive metastatic gastric cancer patients: the AMNESIA case-control studyprimary resistance to trastuzumab in HER2+ gastric cancer. Clin Cancer Res. 2018;24(5):1082\u20139.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1669_CR26","doi-asserted-by":"publisher","first-page":"R110","DOI":"10.1186\/bcr3577","volume":"15","author":"C Hudis","year":"2013","unstructured":"Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, et al. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res. 2013;15(6):R110.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1669_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10549-016-3701-7","volume":"155","author":"AJ Chien","year":"2016","unstructured":"Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, et al. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016;155(3):521\u201330.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"1669_CR28","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.19.01027","volume":"38","author":"AJ Chien","year":"2020","unstructured":"Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, et al. MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and\/or hormone receptor-negative breast cancers in the I-SPY 2 trial. J Clin Oncol. 2020;38(10):1059\u201369.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1669_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ccr.2009.03.016","volume":"15","author":"Y Wu","year":"2009","unstructured":"Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-\u03baB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15(5):416\u201328.","journal-title":"Cancer Cell"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01669-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01669-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01669-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:08Z","timestamp":1790899448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01669-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1669"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01669-9","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kim J-W reports research support paid to his institution from Debiopharm, MitoImmune, Pyramid Biosciences, Adlai Nortye, Merck Sharp and Dohme, AstraZeneca, Lilly, and Aslan; participation in a Data Safety Monitoring Board or Advisory Board for MedPacto and Lilly. Park H reports research support paid to her institution from Genentech, Mirati Therapeutics\/Bristol Myers Squibbs, Exelixis, AstraZeneca, Tizona, Mersana, Bolt Biotherapeutics, StrataPATH, Chugai, Huaota, D3Bio, Amgen, Idience, Incyte, Pfizer, Alterome, and Yuhan; consulting fees from Merck; honoraria for lectures from Medscape; support for meetings from Amgen and Daiichi Sankyo; and participation in a Data Safety Monitoring Board or Advisory Board for Astellas and Daiichi Sankyo. Aguirre AJ reports consulting for Affini-T Therapeutics, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Celex Oncology, Curie. Bio, Incyte, Kestrel Therapeutics, Merck & Co., Inc., Mirati Therapeutics, Nimbus Therapeutics, Pfizer, Plexium, Quanta Therapeutics, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, Taiho Pharmaceuticals, T-knife Therapeutics, Third Rock Ventures, and Ventus Therapeutics; equity in Riva Therapeutics and Kestrel Therapeutics; and research funding from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Deerfield, Inc., Eli Lilly, Mirati Therapeutics, Nimbus Therapeutics, Novartis, Novo Ventures, Revolution Medicines, Syros Pharmaceuticals, and Verastem. The other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of the Seoul National University Bundang Hospital, Seongnam, Republic of Korea (BA-2112-334-001-02).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}